Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

3.6%

3 terminated/withdrawn out of 83 trials

Success Rate

92.3%

+5.8% vs industry average

Late-Stage Pipeline

41%

34 trials in Phase 3/4

Results Transparency

0 of 36 completed trials have results

Key Signals

18 recruiting

Enrollment Performance

Analytics

N/A

26(38.2%)

Phase 4

25(36.8%)

Phase 3

9(13.2%)

Phase 2

6(8.8%)

Early Phase 1

1(1.5%)

Phase 1

1(1.5%)

68Total

N/A(26)

Phase 4(25)

Phase 3(9)

Phase 2(6)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (83)

Showing 20 of 83 trials

NCT07550673Phase 4Recruiting

Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）

Role: lead

NCT06922877Not ApplicableCompleted

Diagnostic Accuracy of 3-dimensional Imaging Device on Polyps and Adenomas During Colonoscopy

Role: lead

NCT07472309Completed

Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis

Role: lead

NCT07401303Not ApplicableNot Yet Recruiting

Full-time RDI for ESD: Impact on Major Adverse Events and Procedure Time

Role: lead

NCT07344402Not ApplicableRecruiting

Optimization of taVNS Intervention Strategies for Refractory Constipation

Role: lead

NCT07323407Not ApplicableRecruiting

Transcranial Alternating Current Stimulation for Refractory Constipation With Somatic Symptom Disorder

Role: lead

NCT05751967Phase 3Recruiting

Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis

Role: lead

NCT06755541Phase 3Recruiting

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study

Role: lead

NCT06755151Phase 3Recruiting

Fenofibrate in Primary Biliary Cholangitis: a Real World Study

Role: lead

NCT05749822Phase 2Recruiting

Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

Role: lead

NCT07182890Phase 4Recruiting

Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia

Role: lead

NCT07187492Phase 4Recruiting

Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia

Role: lead

NCT07296458Phase 3Recruiting

FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy

Role: lead

NCT07257588Not ApplicableEnrolling By Invitation

The Efficacy of Hyperbaric Oxygen-assisted Treatment for ASUC and Refractory IBD

Role: lead

NCT06998693Completed

A Single-Center Observational Study on the Impact of Symptom Assessment Timing on the Short-Term Efficacy of 5-ASA Therapy in Patients With Initial-Onset or Relapsed Mild-to-Moderate Active Ulcerative Colitis

Role: lead

NCT07129460Phase 4Not Yet Recruiting

Efficacy and Safety of Berberine for Gastric Intestinal Metaplasia

Role: lead

NCT07115472Not ApplicableCompleted

Fluoxetine in Refractory Superior Mesenteric Artery Syndrome by Targeting Comorbid Somatic Symptom Disorder

Role: lead

NCT07104201Early Phase 1Recruiting

Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)

Role: lead

NCT06221722Recruiting

Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation

Role: lead

NCT06962020Recruiting

Selection and Efficacy-Influencing Factors of First-Line Biologic Agents in Moderate-to-Severe Ulcerative Colitis

Role: lead